A Phase III, Double-Blind, Placebo-Controlled, Multicenter Study on the Efficacy of Recombinant Human Antithrombin in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass